Summary
Amir F Heshmatpour, who serves as President of NeonC Technologies Holdings, Inc. (NASDAQ:NTHI), reported direct purchases of the company's common stock in filings with the Securities and Exchange Commission. The Form 4 shows a combined 25,000-share acquisition for $153,398 in two transactions executed on April 2 and April 6, 2026. The insider buying arrives as the stock has recently weakened from its 52-week high, and the company has announced several operational and financial developments, including a private placement, a legal settlement, a senior accounting hire, and an upcoming clinical data presentation.
Insider transactions and holdings
The SEC filing details that Heshmatpour bought 20,000 shares on April 2, 2026, at per-share prices ranging from $6.0219 to $6.1579. He later acquired 5,000 shares on April 6, 2026, at $6.32 per share. The aggregate value of these transactions is $153,398. Following these purchases, Heshmatpour is reported to directly own 3,017,000 shares of NeonC Technologies.
The filing also lists indirect holdings attributed to entities associated with Heshmatpour: HCWG LLC owns 256,120 shares, KIG LLC holds 550,000 shares, and AFH Holdings & Advisory, LLC holds 3,714,020 shares.
Share-price context and valuation signals
The insider buys coincide with a recent pullback in the company's stock price. Over the past week the shares have declined by 18% and were trading at $5.74, which is substantially lower than the 52-week high of $12.99. An InvestingPro analysis cited in company commentary indicates the stock appears undervalued relative to its Fair Value assessment and notes that the relative strength index, or RSI, suggests the stock is in oversold territory. The company carries a market capitalization of $141.65 million, according to the same source, and the RSI observation was one of 13 InvestingPro tips noted for subscribers.
Corporate developments
In additional corporate disclosures, NeOnc Technologies Holdings, Inc. said it has raised approximately $16 million through a private placement agreement. The planned offering contemplates the sale of up to 2,222,222 shares of common stock paired with five-year warrants, with a purchase price of $7.20 per share and an exercise price on the warrants of $9.00 per share.
The company also resolved a legal dispute with Fox Infused, LLC, agreeing to a settlement payment of $737,920.77. The settlement follows termination of a prior agreement between the two parties, as disclosed by the company.
Leadership and clinical timeline
NeOnc Technologies announced the appointment of David Choi as Chief Accounting Officer. Choi will oversee the company’s accounting and financial reporting functions. Separately, the company is scheduled to present Phase 1 trial data on March 4, 2026, related to its NEO212-01 clinical trial for central nervous system malignancies. The March presentation will address safety, toxicity, and pharmacokinetic findings and will describe planned regulatory steps following the Phase 1 results.
Contextual note
These disclosures - insider purchases, the private placement, settlement payment, a finance leadership appointment, and the upcoming clinical presentation - together represent a cluster of financial, legal, personnel, and clinical updates that shareholders and market participants may weigh when assessing NeonC/NeOnc’s near-term outlook.